Literature DB >> 21885620

Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states.

Dustin K Williams1, Jingyi Wang, Roger L Papke.   

Abstract

Although α7 nicotinic acetylcholine receptors are considered potentially important therapeutic targets, the development of selective agonists has been stymied by the α7 receptor's intrinsically low probability of opening (P(open)) and the concern that an agonist-based therapeutic approach would disrupt endogenous cholinergic function. Development of α7 positive allosteric modulators (PAMs) holds promise of avoiding both issues. N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea (PNU-120596) is one of the most effective α7 PAMs, with a mechanism associated, at least in part, with the destabilization of desensitized states. We studied the mechanism of PNU-120596 potentiation of α7 receptors expressed in Xenopus laevis oocytes and outside-out patches from BOSC 23 cells. We identify two forms of α7 desensitization: one is destabilized by PNU-120596 (D(s)), and the other is induced by strong episodes of activation and is stable in the presence of the PAM (D(i)). Our characterization of prolonged bursts of single-channel currents that occur with PNU-120596 provide a remarkable contrast to the behavior of the channels in the absence of the PAM. Individual channels that avoid the D(i) state show a 100,000-fold increase in P(open) compared with receptors in the nonpotentiated state. In the presence of PNU-120596, balance between D(s) and D(i) is dynamically regulated by both agonist and PAM binding, with maximal ion channel activity at intermediate levels of binding to both classes of sites. In the presence of high agonist concentrations, competitive antagonists may have the effect of shifting the balance in favor of D(s) and increasing ion channel currents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21885620      PMCID: PMC3228536          DOI: 10.1124/mol.111.074302

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  39 in total

1.  Restoration of single-channel currents using the segmental k-means method based on hidden Markov modeling.

Authors:  Feng Qin
Journal:  Biophys J       Date:  2004-03       Impact factor: 4.033

2.  Functional characterization and high-throughput screening of positive allosteric modulators of α7 nicotinic acetylcholine receptors in IMR-32 neuroblastoma cells.

Authors:  Sujatha M Gopalakrishnan; Betsy M Philip; Jens Halvard Gronlien; John Malysz; David J Anderson; Murali Gopalakrishnan; Usha Warrior; David J Burns
Journal:  Assay Drug Dev Technol       Date:  2011-02-10       Impact factor: 1.738

3.  alpha7 receptor-selective agonists and modes of alpha7 receptor activation.

Authors:  R L Papke; E Meyer; T Nutter; V V Uteshev
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

Review 4.  Structural and functional properties of the acetylcholine receptor protein in its purified and membrane-bound states.

Authors:  T Heidmann; J P Changeux
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

5.  Choline and acetylcholine have similar kinetic properties of activation and desensitization on the alpha7 nicotinic receptors in rat hippocampal neurons.

Authors:  A Mike; N G Castro; E X Albuquerque
Journal:  Brain Res       Date:  2000-11-03       Impact factor: 3.252

6.  The C. elegans ric-3 gene is required for maturation of nicotinic acetylcholine receptors.

Authors:  Sarah Halevi; Jim McKay; Mark Palfreyman; Lina Yassin; Margalit Eshel; Erik Jorgensen; Millet Treinin
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

7.  Fast events in single-channel currents activated by acetylcholine and its analogues at the frog muscle end-plate.

Authors:  D Colquhoun; B Sakmann
Journal:  J Physiol       Date:  1985-12       Impact factor: 5.182

8.  Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.

Authors:  Roger L Papke; Julia K Porter Papke
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

9.  Human alpha4beta2 acetylcholine receptors formed from linked subunits.

Authors:  Yan Zhou; Mark E Nelson; Alexander Kuryatov; Catherine Choi; John Cooper; Jon Lindstrom
Journal:  J Neurosci       Date:  2003-10-08       Impact factor: 6.167

10.  Inhibition of nicotinic acetylcholine receptors by bis (2,2,6,6-tetramethyl- 4-piperidinyl) sebacate (Tinuvin 770), an additive to medical plastics.

Authors:  R L Papke; A G Craig; S F Heinemann
Journal:  J Pharmacol Exp Ther       Date:  1994-02       Impact factor: 4.030

View more
  56 in total

1.  Critical Molecular Determinants of α7 Nicotinic Acetylcholine Receptor Allosteric Activation: SEPARATION OF DIRECT ALLOSTERIC ACTIVATION AND POSITIVE ALLOSTERIC MODULATION.

Authors:  Nicole A Horenstein; Roger L Papke; Abhijit R Kulkarni; Ganesh U Chaturbhuj; Clare Stokes; Khan Manther; Ganesh A Thakur
Journal:  J Biol Chem       Date:  2016-01-07       Impact factor: 5.157

2.  Discovery of an intrasubunit nicotinic acetylcholine receptor-binding site for the positive allosteric modulator Br-PBTC.

Authors:  Jack Norleans; Jingyi Wang; Alexander Kuryatov; Abba Leffler; Christelle Doebelin; Theodore M Kamenecka; Jon Lindstrom
Journal:  J Biol Chem       Date:  2019-06-20       Impact factor: 5.157

3.  Multiple modes of α7 nAChR noncompetitive antagonism of control agonist-evoked and allosterically enhanced currents.

Authors:  Can Peng; Matthew R Kimbrell; Chengju Tian; Thomas F Pack; Peter A Crooks; E Kim Fifer; Roger L Papke
Journal:  Mol Pharmacol       Date:  2013-07-09       Impact factor: 4.436

Review 4.  Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Jingyi Wang; Jon Lindstrom
Journal:  Br J Pharmacol       Date:  2017-03-20       Impact factor: 8.739

5.  Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant β Subunits Acquire Sensitivity to α7-Selective Positive Allosteric Modulators.

Authors:  Clare Stokes; Sumanta Garai; Abhijit R Kulkarni; Lucas N Cantwell; Colleen M Noviello; Ryan E Hibbs; Nicole A Horenstein; Khalil A Abboud; Ganesh A Thakur; Roger L Papke
Journal:  J Pharmacol Exp Ther       Date:  2019-06-07       Impact factor: 4.030

6.  Identification of α7 Nicotinic Acetylcholine Receptor Silent Agonists Based on the Spirocyclic Quinuclidine-Δ2 -Isoxazoline Scaffold: Synthesis and Electrophysiological Evaluation.

Authors:  Marta Quadri; Carlo Matera; Almin Silnović; Maria Chiara Pismataro; Nicole A Horenstein; Clare Stokes; Roger L Papke; Clelia Dallanoce
Journal:  ChemMedChem       Date:  2017-06-12       Impact factor: 3.466

7.  Activation of the α7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT₁a receptor antagonist.

Authors:  Anshul A Pandya; Jerrel L Yakel
Journal:  Neuropharmacology       Date:  2013-01-12       Impact factor: 5.250

8.  The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor.

Authors:  Roger L Papke; Deniz Bagdas; Abhijit R Kulkarni; Timothy Gould; Shakir D AlSharari; Ganesh A Thakur; M Imad Damaj
Journal:  Neuropharmacology       Date:  2014-12-11       Impact factor: 5.250

9.  Expeditious synthesis, enantiomeric resolution, and enantiomer functional characterization of (4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (4BP-TQS): an allosteric agonist-positive allosteric modulator of α7 nicotinic acetylcholine receptors.

Authors:  Ganesh A Thakur; Abhijit R Kulkarni; Jeffrey R Deschamps; Roger L Papke
Journal:  J Med Chem       Date:  2013-10-25       Impact factor: 7.446

10.  Pharmacological modulation of the α7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal.

Authors:  Asti Jackson; Roger L Papke; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.